DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3206-632-638$20.00
DMD 32:632-638, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderton, M. J.
Right arrow Articles by Mager, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderton, M. J.
Right arrow Articles by Mager, D. E.

PHYSIOLOGICAL MODELING OF FORMULATED AND CRYSTALLINE 3,3'-DIINDOLYLMETHANE PHARMACOKINETICS FOLLOWING ORAL ADMINISTRATION IN MICE

Mark J. Anderton, Margaret M. Manson, Richard Verschoyle, Andreas Gescher, William P. Steward, Marion L. Williams, and Donald E. Mager

Departments of Biochemistry and Cancer Studies, University of Leicester, Leicester, United Kingdom (M.J.A., M.M.M., R.V., A.G., W.P.S., M.L.W.); and National Institute on Aging, Gerontology Research Center, Baltimore, Maryland (M.L.W., D.E.M.)

3,3'-Diindolylmethane (DIM) is a naturally occurring indole, which is currently under investigation as a potential chemopreventive agent. The concentrations of DIM in plasma, liver, kidney, lung, heart, and brain tissues were determined following oral administration of two different formulations to mice (250 mg/kg). Mice were sacrificed periodically from 0 to 24 h after administration of either a crystalline or an absorption-enhanced formulation (Bio-Response-DIM; Indolplex) of DIM, and plasma and tissue concentrations were determined by high-performance liquid chromatography (UV detection, 280 nm). A physiologically based pharmacokinetic (PBPK) model was developed to characterize the pharmacokinetic properties of the two different formulations. The final model included parameters reflecting linear first-order absorption, systemic clearance, and distributional clearance in the remainder compartment, which were considered independent of formulation. All pharmacokinetic profiles from the two formulations were fitted simultaneously to estimate unknown model parameters. Plasma and tissue concentration-time profiles exhibited a rapid rise to peak values at 0.5 to 1 h, followed by a polyexponential decline with an extended terminal phase. These profiles were well described by the final model and unknown parameters were estimated with relatively low coefficients of variation. Relative drug exposure and absorption parameters suggest that BioResponse-DIM exhibited approximately 50% higher bioavailability than the crystalline formulation. Clearance of DIM was estimated as 7.18 ml/h. This is the first study to characterize the pharmacokinetics of DIM in mice, and the established PBPK model should prove useful in the design and analysis of future preclinical studies aimed at evaluating the in vivo pharmacological effects of DIM.


Address correspondence to: Dr. Marion L. Williams, National Institute on Aging, Gerontology Research Center, 5600 Nathan Shock Drive, Baltimore, MD 21224. E-mail: williamsma{at}grc.nia.nih.gov




This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Li, T. G. VandenBoom II, D. Kong, Z. Wang, S. Ali, P. A. Philip, and F. H. Sarkar
Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells
Cancer Res., August 15, 2009; 69(16): 6704 - 6712.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Fan, Q. Meng, T. Saha, F. H. Sarkar, and E. M. Rosen
Low Concentrations of Diindolylmethane, a Metabolite of Indole-3-Carbinol, Protect against Oxidative Stress in a BRCA1-Dependent Manner
Cancer Res., August 1, 2009; 69(15): 6083 - 6091.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
E. P. Moiseeva and M. M. Manson
Dietary Chemopreventive Phytochemicals: Too Little or Too Much?
Cancer Prevention Research, July 1, 2009; 2(7): 611 - 616.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
F. S. Khwaja, S. Wynne, I. Posey, and D. Djakiew
3,3'-Diindolylmethane Induction of p75NTR-Dependent Cell Death via the p38 Mitogen-Activated Protein Kinase Pathway in Prostate Cancer Cells
Cancer Prevention Research, June 1, 2009; 2(6): 566 - 571.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
G. Gao and F. C. P. Law
Physiologically Based Pharmacokinetics of Matrine in the Rat after Oral Administration of Pure Chemical and ACAPHA
Drug Metab. Dispos., April 1, 2009; 37(4): 884 - 891.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
S. T. Okino, D. Pookot, S. Basak, and R. Dahiya
Toxic and Chemopreventive Ligands Preferentially Activate Distinct Aryl Hydrocarbon Receptor Pathways: Implications for Cancer Prevention
Cancer Prevention Research, March 1, 2009; 2(3): 251 - 256.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. A. Reed, J. M. Sunega, D. K. Sullivan, J. C. Gray, M. S. Mayo, J. A. Crowell, and A. Hurwitz
Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3,3'-Diindolylmethane in Healthy Subjects
Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2619 - 2624.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
H. J. Cho, M. R. Seon, Y. M. Lee, J. Kim, J.-K. Kim, S. G. Kim, and J. H. Y. Park
3,3'-Diindolylmethane Suppresses the Inflammatory Response to Lipopolysaccharide in Murine Macrophages
J. Nutr., January 1, 2008; 138(1): 17 - 23.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Li, Z. Wang, D. Kong, S. Murthy, Q. P. Dou, S. Sheng, G. P. V. Reddy, and F. H. Sarkar
Regulation of FOXO3a/beta-Catenin/GSK-3beta Signaling by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells
J. Biol. Chem., July 20, 2007; 282(29): 21542 - 21550.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. A. Reed, D. W. Arneson, W. C. Putnam, H. J. Smith, J. C. Gray, D. K. Sullivan, M. S. Mayo, J. A. Crowell, and A. Hurwitz
Single-Dose and Multiple-Dose Administration of Indole-3-Carbinol to Women: Pharmacokinetics Based on 3,3'-Diindolylmethane
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2477 - 2481.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. M.R. Bhuiyan, Y. Li, S. Banerjee, F. Ahmed, Z. Wang, S. Ali, and F. H. Sarkar
Down-regulation of Androgen Receptor by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Both Hormone-Sensitive LNCaP and Insensitive C4-2B Prostate Cancer Cells.
Cancer Res., October 15, 2006; 66(20): 10064 - 10072.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.